SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals
INFI 0.0160-4.8%Sep 29 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (39)7/2/2006 8:46:21 PM
From: Mike McFarland  Read Replies (1) of 210
 
MMRF Spring Newsletter, page nine has
a list of emerging therapies for MM

multiplemyeloma.org

Atiprimod (Callisto Pharmaceuticals)
IPI-504 (Infinity Pharmaceuticals, Inc.)
KOS-953 (Kosan Biosciences)
Perifosine (Keryx)
PR171 (Proteolix)
SGN-40 (Seattle Genetics)

Emerging Targeted Therapies in Preclinical Development
ABT-737 (Abbott)
CHIR-12.12(Chiron)
GRN163L (Geron)
NPI-0052 (Nereus)
NPI-1387 (Nereus)
PKC412 (Novartis)
Tubacin

Here is the old list of competitors:
Kosan
Astex
Synta
Arqule
Serenex
Neutec
Vernalis

and from the dpii s-4

Infinity believes that Kosan Biosciences, Conforma Therapeutics Corporation (which recently announced its proposed acquisition by BiogenIdec Inc.), Serenex, Inc., Vernalis plc (in collaboration with Novartis) and Synta Pharmaceuticals have preclinical and early clinical stage development programs seeking to develop compounds that target Heat Shock Protein 90, or Hsp90, which is the target of Infinity’s lead compound IPI-504. Curis, Inc. and Genentech Inc. have an early stage clinical development collaboration seeking to develop drugs that target the Hedgehog signaling pathway, which is the target of Infinity’s IPI-609 preclinical compound. Gemin-X Biosciences and Abbott Laboratories are believed to be in early-stage development of compounds to target the Bcl-2 family of proteins, which is the target of an Infinity discovery effort as well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News